Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/23127
Title: | Early clinical markers of aggressive multiple sclerosis. | Austin Authors: | Malpas, Charles B;Manouchehrinia, Ali;Sharmin, Sifat;Roos, Izanne;Horakova, Dana;Havrdova, Eva Kubala;Trojano, Maria;Izquierdo, Guillermo;Eichau, Sara;Bergamaschi, Roberto;Sola, Patrizia;Ferraro, Diana;Lugaresi, Alessandra;Prat, Alexandre;Girard, Marc;Duquette, Pierre;Grammond, Pierre;Grand'Maison, Francois;Ozakbas, Serkan;Van Pesch, Vincent;Granella, Franco;Hupperts, Raymond;Pucci, Eugenio;Boz, Cavit;Sidhom, Youssef;Gouider, Riadh;Spitaleri, Daniele;Soysal, Aysun;Petersen, Thor;Verheul, Freek;Karabudak, Rana;Turkoglu, Recai;Ramo-Tello, Cristina;Terzi, Murat;Cristiano, Edgardo;Slee, Mark;McCombe, Pamela;Macdonell, Richard A L ;Fragoso, Yara;Olascoaga, Javier;Altintas, Ayse;Olsson, Tomas;Butzkueven, Helmut;Hillert, Jan;Kalincik, Tomas | Affiliation: | Université Catholique de Louvain, Brussels, Belgium Department of Biomedical and Neuromotor Science, University of Bologna, Bologna, Italy IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy Cliniques Universitaires Saint-Luc, Brussels, Belgium CORe Unit, Department of Medicine, University of Melbourne, Melbourne, Australia Centre for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden Flinders University, Adelaide, Australia Royal Brisbane and Women's Hospital, Brisbane, Australia University of Queensland, Brisbane, Australia Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia Department of Neurology, The Alfred Hospital, Melbourne, Australia Central Clinical School, Monash University, Melbourne, Australia Austin Health, Heidelberg, Victoria, Australia Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy Hospital Universitario Virgen Macarena, Sevilla, Spain IRCCS Mondino Foundation, Pavia, Italy Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy CHUM and Universite de Montreal, Montreal, Canada CISSS de Chaudière-Appalaches, Levis, Canada Neuro Rive-Sud, Quebec, Canada Dokuz Eylul University, Konak/Izmir, Turkey Department of Medicine and Surgery, University of Parma, Parma, Italy Zuyderland Ziekenhuis, Sittard, The Netherlands UOC Neurologia, Azienda Sanitaria Unica Regionale Marche - AV3, Macerata, Italy KTU Medical Faculty Farabi Hospital, Trabzon, Turkey Department of Neurology, Razi Hospital, Manouba, Tunisia Department of Neurology, Razi Hospital, LR 18SP03, Clinical Investigation Center Neurosciences and Mental Health, Faculty of Medicine University Tunis El Manar, Tunis, Tunisia Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey Kommunehospitalet, Arhus C, Denmark Groene Hart Ziekenhuis, Gouda, The Netherlands Hacettepe University, Ankara, Turkey Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey Hospital Germans Trias i Pujol, Badalona, Spain Medical Faculty, 19 Mayis University, Samsun, Turkey Hospital Italiano, Buenos Aires, Argentina Universidade Metropolitana de Santos, Santos, Brazil Instituto de Investigación Sanitaria Biodonostia, Hospital Universitario Donostia, San Sebastián, Spain Koc University, School of Medicine, Department of Neurology, Istanbul, Turkey Department of Clinical Neuroscience, Karolinska Institutet, Sweden |
Issue Date: | 9-May-2020 | Date: | 2020-05-09 | Publication information: | Brain : a journal of neurology 2020; online first: 9 May | Abstract: | Patients with the 'aggressive' form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Disability Status Score (EDSS) ≥ 6 within 10 years of symptom onset. Several clinicodemographic factors have been associated with aggressive multiple sclerosis, but less research has focused on clinical markers that are present in the first year of disease. The development of early predictive models of aggressive multiple sclerosis is essential to optimize treatment in this multiple sclerosis subtype. We evaluated whether patients who will develop aggressive multiple sclerosis can be identified based on early clinical markers. We then replicated this analysis in an independent cohort. Patient data were obtained from the MSBase observational study. Inclusion criteria were (i) first recorded disability score (EDSS) within 12 months of symptom onset; (ii) at least two recorded EDSS scores; and (iii) at least 10 years of observation time, based on time of last recorded EDSS score. Patients were classified as having 'aggressive multiple sclerosis' if all of the following criteria were met: (i) EDSS ≥ 6 reached within 10 years of symptom onset; (ii) EDSS ≥ 6 confirmed and sustained over ≥6 months; and (iii) EDSS ≥ 6 sustained until the end of follow-up. Clinical predictors included patient variables (sex, age at onset, baseline EDSS, disease duration at first visit) and recorded relapses in the first 12 months since disease onset (count, pyramidal signs, bowel-bladder symptoms, cerebellar signs, incomplete relapse recovery, steroid administration, hospitalization). Predictors were evaluated using Bayesian model averaging. Independent validation was performed using data from the Swedish Multiple Sclerosis Registry. Of the 2403 patients identified, 145 were classified as having aggressive multiple sclerosis (6%). Bayesian model averaging identified three statistical predictors: age > 35 at symptom onset, EDSS ≥ 3 in the first year, and the presence of pyramidal signs in the first year. This model significantly predicted aggressive multiple sclerosis [area under the curve (AUC) = 0.80, 95% confidence intervals (CIs): 0.75, 0.84, positive predictive value = 0.15, negative predictive value = 0.98]. The presence of all three signs was strongly predictive, with 32% of such patients meeting aggressive disease criteria. The absence of all three signs was associated with a 1.4% risk. Of the 556 eligible patients in the Swedish Multiple Sclerosis Registry cohort, 34 (6%) met criteria for aggressive multiple sclerosis. The combination of all three signs was also predictive in this cohort (AUC = 0.75, 95% CIs: 0.66, 0.84, positive predictive value = 0.15, negative predictive value = 0.97). Taken together, these findings suggest that older age at symptom onset, greater disability during the first year, and pyramidal signs in the first year are early indicators of aggressive multiple sclerosis. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/23127 | DOI: | 10.1093/brain/awaa081 | Journal: | Brain : a journal of neurology | PubMed URL: | 32386427 | Type: | Journal Article | Subjects: | aggressive disease disability multiple sclerosis precision medicine prediction |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.